Nektar Therapeutics (FRA:ITH0) Cyclically Adjusted Revenue per Share: €19.47 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:ITH0 Nektar Therapeutics FRA:ITH0
47 GF Score
Price €60.70
GF Value €5.14
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Nektar Therapeutics Cyclically Adjusted Revenue per Share?

Nektar Therapeutics FRA:ITH0 -3.13% 47 Cyclically Adjusted Revenue per Share is €19.47 as of Mar. 2026. GuruFocus rates FRA:ITH0 with a GF Score™ of 47/100 and a GF Value™ of €5.14 (Significantly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Nektar Therapeutics's adjusted revenue per share for the three months ended in Mar. 2026 was €0.380. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €19.47 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Nektar Therapeutics's average Cyclically Adjusted Revenue Growth Rate was -6.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -5.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -1.40% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 2.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Nektar Therapeutics was 16.80% per year. The lowest was -5.80% per year. And the median was 0.50% per year.

As of today (2026-07-14), Nektar Therapeutics's current stock price is €60.70. Nektar Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €19.47. Nektar Therapeutics's Cyclically Adjusted PS Ratio of today is 3.12.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Nektar Therapeutics was 81.75. The lowest was 0.23. And the median was 8.49.


Nektar Therapeutics  (FRA:ITH0) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Nektar Therapeutics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=60.70/19.47
=3.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Nektar Therapeutics was 81.75. The lowest was 0.23. And the median was 8.49.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Nektar Therapeutics Cyclically Adjusted Revenue per Share Related Terms


Nektar Therapeutics Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Nektar Therapeutics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nektar Therapeutics Cyclically Adjusted Revenue per Share Chart

Nektar Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 26.72 27.52 25.64 26.74 21.26

Nektar Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.10 22.26 22.53 21.26 19.47

FRA:ITH0 vs OCUL, PVLA, GENB: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Nektar Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nektar Therapeutics Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nektar Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Nektar Therapeutics's Cyclically Adjusted PS Ratio falls into.


FRA:ITH0
47GF Score
Nektar Therapeutics FRA:ITH0
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nektar Therapeutics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Nektar Therapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.38/330.2130*330.2130
=0.380

Current CPI (Mar. 2026) = 330.2130.

Nektar Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 3.208 241.018 4.395
201609 3.542 241.428 4.845
201612 3.571 241.432 4.884
201703 2.257 243.801 3.057
201706 2.972 244.955 4.006
201709 11.833 246.819 15.831
201712 7.641 246.524 10.235
201803 2.875 249.554 3.804
201806 76.614 251.989 100.397
201809 2.067 252.439 2.704
201812 2.891 251.233 3.800
201903 2.155 254.202 2.799
201906 1.773 256.143 2.286
201909 2.269 256.759 2.918
201912 2.595 256.974 3.335
202003 3.875 258.115 4.957
202006 3.649 257.797 4.674
202009 2.136 260.280 2.710
202012 1.610 260.474 2.041
202103 1.643 264.877 2.048
202106 1.931 271.696 2.347
202109 1.726 274.310 2.078
202112 1.795 278.802 2.126
202203 1.819 287.504 2.089
202206 1.640 296.311 1.828
202209 1.908 296.808 2.123
202212 1.657 296.797 1.844
202303 1.602 301.836 1.753
202306 1.496 305.109 1.619
202309 1.782 307.789 1.912
202312 1.720 306.746 1.852
202403 1.533 312.332 1.621
202406 1.567 314.175 1.647
202409 1.558 315.301 1.632
202412 1.992 315.605 2.084
202503 0.688 319.799 0.710
202506 0.688 322.561 0.704
202509 0.530 324.800 0.539
202512 0.916 324.054 0.933
202603 0.380 330.213 0.380

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €19.47 mean?
Nektar Therapeutics (FRA:ITH0) has a Cyclically Adjusted Revenue per Share of €19.47 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Nektar Therapeutics and its competitors.
Is Nektar Therapeutics' Cyclically Adjusted Revenue per Share too high?
Nektar Therapeutics' current Cyclically Adjusted Revenue per Share is €19.47. Overall, Nektar Therapeutics has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nektar Therapeutics' Cyclically Adjusted Revenue per Share compare to OCUL and PVLA?
Nektar Therapeutics' Cyclically Adjusted Revenue per Share of €19.47 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Nektar Therapeutics and its competitors. Nektar Therapeutics's current Cyclically Adjusted Revenue per Share is €19.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nektar Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Nektar Therapeutics (FRA:ITH0) is currently considered Significantly Overvalued. The stock's GF Value™ is €5.14, compared to a current price of €60.70 — trading 1080.9% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €19.47. Nektar Therapeutics' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Nektar Therapeutics (FRA:ITH0), the current Cyclically Adjusted Revenue per Share is €19.47 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nektar Therapeutics (FRA:ITH0) Overvalued in 2026?

Based on GuruFocus' analysis, Nektar Therapeutics stock appears to be overvalued. The current stock price of €60.70 is trading 1080.9% above its estimated GF Value™ of €5.14. GuruFocus considers Nektar Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:ITH0:

  • Cyclically Adjusted Revenue per Share: €19.47
  • GF Value™: €5.14 vs. price of €60.70 (1080.9% above fair value)
  • GF Score™: 47/100 with 5 warning signs

No single metric tells the full story. See the FRA:ITH0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Nektar Therapeutics Business Description

Other Exchanges NKTR:USA0UNL:UKITH0:Germany
Address 455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
47GF Score

Get the complete analysis for FRA:ITH0

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€60.70
Price
€5.14
GF Value